These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
(Mark One)
|
|
|
|
|
|
|
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
|
|
Large Accelerated Filer
þ
|
|
Accelerated Filer
o
|
|
|
Non-Accelerated Filer
o
|
|
Smaller Reporting Company
o
|
|
|
(Do not check if a smaller reporting company.)
|
Emerging Growth Company
o
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions except per share data - unaudited)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Sales
|
$
|
870
|
|
|
$
|
790
|
|
|
$
|
2,380
|
|
|
$
|
2,265
|
|
|
Cost of sales
|
635
|
|
|
554
|
|
|
1,727
|
|
|
1,581
|
|
||||
|
Gross profit
|
235
|
|
|
236
|
|
|
653
|
|
|
684
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Selling, general and administrative expense
|
182
|
|
|
160
|
|
|
493
|
|
|
481
|
|
||||
|
Research and development expense
|
20
|
|
|
22
|
|
|
61
|
|
|
66
|
|
||||
|
Equity and other income
|
4
|
|
|
3
|
|
|
9
|
|
|
7
|
|
||||
|
Operating income
|
37
|
|
|
57
|
|
|
108
|
|
|
144
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Net interest and other financing expense
|
51
|
|
|
40
|
|
|
203
|
|
|
125
|
|
||||
|
Net gain (loss) on acquisitions and divestitures
|
(6
|
)
|
|
3
|
|
|
(7
|
)
|
|
3
|
|
||||
|
Income (loss) from continuing operations
|
|
|
|
|
|
|
|
||||||||
|
before income taxes
|
(20
|
)
|
|
20
|
|
|
(102
|
)
|
|
22
|
|
||||
|
Income tax benefit - Note I
|
(4
|
)
|
|
(4
|
)
|
|
(49
|
)
|
|
(39
|
)
|
||||
|
Income (loss) from continuing operations
|
(16
|
)
|
|
24
|
|
|
(53
|
)
|
|
61
|
|
||||
|
Income (loss) from discontinued operations
|
|
|
|
|
|
|
|
||||||||
|
(net of tax) - Note D
|
(14
|
)
|
|
47
|
|
|
138
|
|
|
186
|
|
||||
|
Net income (loss)
|
(30
|
)
|
|
71
|
|
|
85
|
|
|
247
|
|
||||
|
Net income attributable to noncontrolling interest
(a)
|
3
|
|
|
—
|
|
|
27
|
|
|
—
|
|
||||
|
Net income (loss) attributable to Ashland
|
$
|
(33
|
)
|
|
$
|
71
|
|
|
$
|
58
|
|
|
$
|
247
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
PER SHARE DATA
|
|
|
|
|
|
|
|
||||||||
|
Basic earnings per share - Note L
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Income (loss) from continuing operations
|
|
|
|
|
|
|
|
||||||||
|
attributable to Ashland
|
$
|
(0.26
|
)
|
|
$
|
0.39
|
|
|
$
|
(0.85
|
)
|
|
$
|
0.97
|
|
|
Income (loss) from discontinued operations
|
(0.28
|
)
|
|
0.76
|
|
|
1.78
|
|
|
2.94
|
|
||||
|
Net income (loss) attributable to Ashland
|
$
|
(0.54
|
)
|
|
$
|
1.15
|
|
|
$
|
0.93
|
|
|
$
|
3.91
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Diluted earnings per share - Note L
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Income (loss) from continuing operations
|
|
|
|
|
|
|
|
||||||||
|
attributable to Ashland
|
$
|
(0.26
|
)
|
|
$
|
0.38
|
|
|
$
|
(0.85
|
)
|
|
$
|
0.95
|
|
|
Income (loss) from discontinued operations
|
(0.28
|
)
|
|
0.75
|
|
|
1.78
|
|
|
2.92
|
|
||||
|
Net income (loss) attributable to Ashland
|
$
|
(0.54
|
)
|
|
$
|
1.13
|
|
|
$
|
0.93
|
|
|
$
|
3.87
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
DIVIDENDS PAID PER COMMON SHARE
|
$
|
0.225
|
|
|
$
|
0.390
|
|
|
$
|
1.005
|
|
|
$
|
1.170
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
COMPREHENSIVE INCOME (LOSS)
|
|
|
|
|
|
|
|
||||||||
|
Net income (loss)
|
$
|
(30
|
)
|
|
$
|
71
|
|
|
$
|
85
|
|
|
$
|
247
|
|
|
Other comprehensive income (loss), net of tax - Note M
|
|
|
|
|
|
|
|
||||||||
|
Unrealized translation gain (loss)
|
105
|
|
|
(46
|
)
|
|
19
|
|
|
(26
|
)
|
||||
|
Pension and postretirement obligation adjustment
|
—
|
|
|
—
|
|
|
(4
|
)
|
|
21
|
|
||||
|
Net change in available-for-sale securities
|
4
|
|
|
4
|
|
|
10
|
|
|
13
|
|
||||
|
Other comprehensive income (loss)
|
109
|
|
|
(42
|
)
|
|
25
|
|
|
8
|
|
||||
|
Comprehensive income
|
$
|
79
|
|
|
$
|
29
|
|
|
$
|
110
|
|
|
$
|
255
|
|
|
Comprehensive income attributable to noncontrolling interest
|
3
|
|
|
—
|
|
|
27
|
|
|
—
|
|
||||
|
Comprehensive income attributable to Ashland
|
$
|
76
|
|
|
$
|
29
|
|
|
$
|
83
|
|
|
$
|
255
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
(a)
|
Represents the income attributable to the previous noncontrolling interest in Valvoline Inc., whose results are now included within discontinued operations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30
|
|
|
September 30
|
|
||
|
(In millions - unaudited)
|
2017
|
|
|
2016
|
|
||
|
|
|
|
|
||||
|
ASSETS
|
|
|
|
||||
|
Current assets
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
492
|
|
|
$
|
1,017
|
|
|
Accounts receivable
(a)
|
643
|
|
|
529
|
|
||
|
Inventories - Note F
|
631
|
|
|
539
|
|
||
|
Other assets
|
73
|
|
|
89
|
|
||
|
Current assets of discontinued operations - Note D
|
—
|
|
|
714
|
|
||
|
Total current assets
|
1,839
|
|
|
2,888
|
|
||
|
Noncurrent assets
|
|
|
|
|
|
||
|
Property, plant and equipment
|
|
|
|
||||
|
Cost
|
3,707
|
|
|
3,615
|
|
||
|
Accumulated depreciation
|
1,770
|
|
|
1,715
|
|
||
|
Net property, plant and equipment
|
1,937
|
|
|
1,900
|
|
||
|
Goodwill - Note G
|
2,426
|
|
|
2,138
|
|
||
|
Intangibles - Note G
|
1,316
|
|
|
1,061
|
|
||
|
Restricted investments - Note E
|
299
|
|
|
292
|
|
||
|
Asbestos insurance receivable - Note K
|
211
|
|
|
196
|
|
||
|
Equity and other unconsolidated investments
|
32
|
|
|
31
|
|
||
|
Deferred income taxes
|
35
|
|
|
35
|
|
||
|
Other assets
|
411
|
|
|
406
|
|
||
|
Noncurrent assets of discontinued operations - Note D
|
—
|
|
|
1,053
|
|
||
|
Total noncurrent assets
|
6,667
|
|
|
7,112
|
|
||
|
Total assets
|
$
|
8,506
|
|
|
$
|
10,000
|
|
|
|
|
|
|
||||
|
LIABILITIES AND EQUITY
|
|
|
|
|
|
||
|
Current liabilities
|
|
|
|
|
|
||
|
Short-term debt - Note H
|
$
|
223
|
|
|
$
|
170
|
|
|
Current portion of long-term debt - Note H
|
6
|
|
|
—
|
|
||
|
Trade and other payables
|
392
|
|
|
376
|
|
||
|
Accrued expenses and other liabilities
|
274
|
|
|
313
|
|
||
|
Current liabilities of discontinued operations - Note D
|
—
|
|
|
379
|
|
||
|
Total current liabilities
|
895
|
|
|
1,238
|
|
||
|
Noncurrent liabilities
|
|
|
|
|
|
||
|
Long-term debt - Note H
|
2,584
|
|
|
2,325
|
|
||
|
Employee benefit obligations - Note J
|
191
|
|
|
195
|
|
||
|
Asbestos litigation reserve - Note K
|
702
|
|
|
686
|
|
||
|
Deferred income taxes
|
374
|
|
|
315
|
|
||
|
Other liabilities
|
361
|
|
|
361
|
|
||
|
Noncurrent liabilities of discontinued operations - Note D
|
—
|
|
|
1,715
|
|
||
|
Total noncurrent liabilities
|
4,212
|
|
|
5,597
|
|
||
|
Commitments and contingencies - Note K
|
|
|
|
|
|
||
|
Equity
|
|
|
|
||||
|
Stockholders' equity
|
3,399
|
|
|
3,347
|
|
||
|
Noncontrolling interest
(b)
|
—
|
|
|
(182
|
)
|
||
|
Total equity
|
3,399
|
|
|
3,165
|
|
||
|
Total liabilities and equity
|
$
|
8,506
|
|
|
$
|
10,000
|
|
|
|
|
|
|
||||
|
(a)
|
Accounts receivable includes an allowance for doubtful accounts of
$8 million
and
$10 million
at
June 30, 2017
and
September 30, 2016
, respectively.
|
|
(b)
|
Represents the previous noncontrolling interest in Valvoline Inc. held outside of Ashland which is now included within discontinued operations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In millions - unaudited)
|
Common
stock
|
|
|
Paid-in
capital
|
|
|
Retained
earnings
|
|
|
Accumulated
other
comprehensive
income (loss)
|
|
(a)
|
Noncontrolling interest
|
|
(b)
|
Total
|
|
||||||
|
BALANCE AT SEPTEMBER 30, 2016
|
$
|
1
|
|
|
$
|
923
|
|
|
$
|
2,704
|
|
|
$
|
(281
|
)
|
|
$
|
(182
|
)
|
|
$
|
3,165
|
|
|
Total comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Net income
|
|
|
|
|
|
58
|
|
|
|
|
27
|
|
|
85
|
|
||||||||
|
Other comprehensive loss
|
|
|
|
|
|
|
25
|
|
|
—
|
|
|
25
|
|
|||||||||
|
Regular dividends, $1.005 per common share
|
|
|
|
|
|
|
(62
|
)
|
|
|
|
|
|
|
(62
|
)
|
|||||||
|
Common shares issued under stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
incentive and other plans
(c)
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
3
|
|
||||||||
|
Distribution of Valvoline Inc.
(b)
|
|
|
—
|
|
|
68
|
|
|
(33
|
)
|
|
152
|
|
|
187
|
|
|||||||
|
Other
|
|
|
(7
|
)
|
|
|
|
|
|
7
|
|
|
—
|
|
|||||||||
|
Distributions to noncontrolling interest
|
|
|
|
|
|
|
|
|
(4
|
)
|
|
(4
|
)
|
||||||||||
|
BALANCE AT JUNE 30, 2017
|
$
|
1
|
|
|
$
|
919
|
|
|
$
|
2,768
|
|
|
$
|
(289
|
)
|
|
$
|
—
|
|
|
$
|
3,399
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
(a)
|
At
June 30, 2017
and
September 30, 2016
, the after-tax accumulated other comprehensive loss attributable to Ashland of
$289 million
and
$281 million
, respectively, was comprised of unrecognized prior service credits as a result of certain employee benefit plan amendments of
$3 million
and
$46 million
, respectively, net unrealized translation losses of
$308 million
and
$333 million
, respectively, and net unrealized gain on available-for-sale securities of
$16 million
and
$6 million
, respectively. At
September 30, 2016
, amounts attributable to noncontrolling interest included unrecognized prior service credits of
$9 million
and net unrealized translation losses of
$2 million
. The accumulated other comprehensive income that was distributed to Valvoline Inc. included
$39 million
of unrecognized prior service credits and
$6 million
of net unrealized translation losses.
|
|
(b)
|
See Note B for discussion of the distribution of Valvoline Inc. and the noncontrolling interest.
|
|
(c)
|
Common shares issued were
242,043
for the
nine
months ended
June 30, 2017
.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
||||||
|
|
June 30
|
||||||
|
(In millions - unaudited)
|
2017
|
|
|
2016
|
|
||
|
CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES FROM
|
|
|
|
||||
|
CONTINUING OPERATIONS
|
|
|
|
||||
|
Net income
|
$
|
85
|
|
|
$
|
247
|
|
|
Income from discontinued operations (net of tax)
|
(138
|
)
|
|
(186
|
)
|
||
|
Adjustments to reconcile income from continuing operations to
|
|
|
|
|
|
||
|
cash flows from operating activities
|
|
|
|
|
|
||
|
Depreciation and amortization
|
218
|
|
|
227
|
|
||
|
Original issue discount and debt issuance cost amortization
|
108
|
|
|
9
|
|
||
|
Deferred income taxes
|
(4
|
)
|
|
—
|
|
||
|
Equity income from affiliates
|
—
|
|
|
(1
|
)
|
||
|
Distributions from equity affiliates
|
1
|
|
|
1
|
|
||
|
Stock based compensation expense
|
14
|
|
|
23
|
|
||
|
Loss on early retirement of debt
|
9
|
|
|
—
|
|
||
|
Gain on available-for-sale securities
|
(9
|
)
|
|
(6
|
)
|
||
|
Net loss (gain) on divestitures
|
4
|
|
|
(3
|
)
|
||
|
Pension contributions
|
(6
|
)
|
|
(24
|
)
|
||
|
Loss (gain) on pension and other postretirement plan remeasurements
|
(2
|
)
|
|
18
|
|
||
|
Change in operating assets and liabilities (a)
|
(166
|
)
|
|
(70
|
)
|
||
|
Total cash flows provided by operating activities from continuing operations
|
114
|
|
|
235
|
|
||
|
CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES FROM
|
|
|
|
|
|
||
|
CONTINUING OPERATIONS
|
|
|
|
|
|
||
|
Additions to property, plant and equipment
|
(126
|
)
|
|
(150
|
)
|
||
|
Proceeds from disposal of property, plant and equipment
|
4
|
|
|
3
|
|
||
|
Purchase of operations - net of cash acquired
|
(680
|
)
|
|
—
|
|
||
|
Proceeds from sale of operations or equity investments
|
4
|
|
|
18
|
|
||
|
Net purchase of funds restricted for specific transactions
|
(2
|
)
|
|
(4
|
)
|
||
|
Reimbursements from restricted investments
|
19
|
|
|
24
|
|
||
|
Purchases of available-for-sale securities
|
(19
|
)
|
|
(4
|
)
|
||
|
Proceeds from sales of available-for-sale securities
|
19
|
|
|
4
|
|
||
|
Proceeds from the settlement of derivative instruments
|
5
|
|
|
8
|
|
||
|
Payments for the settlement of derivative instruments
|
(3
|
)
|
|
(2
|
)
|
||
|
Total cash flows used by investing activities from continuing operations
|
(779
|
)
|
|
(103
|
)
|
||
|
CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES FROM
|
|
|
|
|
|
||
|
CONTINUING OPERATIONS
|
|
|
|
|
|
||
|
Proceeds from issuance of long-term debt
|
1,100
|
|
|
—
|
|
||
|
Repayment of long-term debt
|
(913
|
)
|
|
(50
|
)
|
||
|
Premium on long-term debt repayment
|
(17
|
)
|
|
—
|
|
||
|
Proceeds from short-term debt
|
69
|
|
|
389
|
|
||
|
Repurchase of common stock
|
—
|
|
|
(500
|
)
|
||
|
Debt issuance costs
|
(15
|
)
|
|
(2
|
)
|
||
|
Cash dividends paid
|
(62
|
)
|
|
(72
|
)
|
||
|
Excess tax benefits related to share-based payments
|
2
|
|
|
1
|
|
||
|
Total cash flows provided (used) by financing activities from continuing operations
|
164
|
|
|
(234
|
)
|
||
|
CASH USED BY CONTINUING OPERATIONS
|
(501
|
)
|
|
(102
|
)
|
||
|
Cash provided (used) by discontinued operations
|
|
|
|
|
|
||
|
Operating cash flows, net
|
123
|
|
|
170
|
|
||
|
Investing cash flows, net
|
(293
|
)
|
|
(104
|
)
|
||
|
Financing cash flows, net
|
(17
|
)
|
|
—
|
|
||
|
Total cash provided (used) by discontinued operations
|
(187
|
)
|
|
66
|
|
||
|
Effect of currency exchange rate changes on cash and cash equivalents
|
(8
|
)
|
|
(6
|
)
|
||
|
DECREASE IN CASH AND CASH EQUIVALENTS
|
(696
|
)
|
|
(42
|
)
|
||
|
Cash, beginning of period held by Ashland
|
1,017
|
|
|
1,257
|
|
||
|
Cash, beginning of period held by Valvoline and reported as discontinued operations
|
171
|
|
|
—
|
|
||
|
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD
|
1,188
|
|
|
1,257
|
|
||
|
CASH AND CASH EQUIVALENTS - END OF PERIOD
|
$
|
492
|
|
|
$
|
1,215
|
|
|
|
|
|
|
||||
|
(a)
|
Excludes changes resulting from operations acquired or sold.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
||
|
|
||
|
|
May 12
|
|
|
|
(In millions)
|
2017
|
|
|
|
ASSETS
|
|
||
|
Current assets
|
|
||
|
Cash
|
179
|
|
|
|
Accounts receivable, net
|
385
|
|
|
|
Inventories
|
153
|
|
|
|
Other current assets
|
24
|
|
|
|
Total current assets
|
741
|
|
|
|
Noncurrent assets
|
|
||
|
Net property, plant and equipment
|
357
|
|
|
|
Goodwill
|
329
|
|
|
|
Equity and other unconsolidated investments
|
31
|
|
|
|
Deferred income taxes
|
391
|
|
|
|
Other noncurrent assets
|
93
|
|
|
|
Total noncurrent assets
|
1,201
|
|
|
|
Total assets
|
$
|
1,942
|
|
|
LIABILITIES AND EQUITY
|
|
||
|
Current liabilities
|
|
||
|
Short-term debt
|
75
|
|
|
|
Current portion of long-term debt
|
16
|
|
|
|
Trade and other payables
|
353
|
|
|
|
Other current liabilities
|
34
|
|
|
|
Total current liabilities
|
478
|
|
|
|
Noncurrent liabilities
|
|
||
|
Long-term debt
|
662
|
|
|
|
Employee benefit obligations
|
826
|
|
|
|
Other long-term liabilities
|
163
|
|
|
|
Total noncurrent liabilities
|
1,651
|
|
|
|
Total liabilities
|
$
|
2,129
|
|
|
Net deficit
|
$
|
(187
|
)
|
|
|
||
|
|
||
|
|
||
|
|
|
|
|
|
|
|
At
|
|
|
|
|
May 17,
|
|
|
|
Preliminary purchase price allocation (in millions)
|
2017
|
|
|
|
Assets:
|
|
||
|
Accounts receivable
|
53
|
|
|
|
Inventory
|
76
|
|
|
|
Other current assets
|
9
|
|
|
|
Intangible assets
|
312
|
|
|
|
Goodwill
|
276
|
|
|
|
Property, plant and equipment
|
96
|
|
|
|
Other noncurrent assets
|
20
|
|
|
|
Liabilities:
|
|
|
|
|
Accounts payable
|
(23
|
)
|
|
|
Deferred tax - net
|
(128
|
)
|
|
|
Other noncurrent liabilities
|
(11
|
)
|
|
|
Total purchase price
|
$
|
680
|
|
|
|
|
|
Weighted-average
|
||
|
|
|
|
amortization period
|
||
|
Intangible asset type (in millions)
|
Value
|
|
|
(years)
|
|
|
Trademarks and trade names
|
$
|
26
|
|
|
15
|
|
Intellectual property
|
69
|
|
|
22
|
|
|
Customer and supplier relationships
|
217
|
|
|
20
|
|
|
Total
|
$
|
312
|
|
|
|
|
|
|
|
|
|
|
Pharmachem results of operations
|
Nine months ended
|
|
||
|
(In millions)
|
June 30, 2017
|
(a)
|
||
|
Sales
|
$
|
36
|
|
|
|
Operating income
|
4
|
|
|
|
|
|
|
|
||
|
(a)
|
Amounts represent the sales and results of operations for the period May 17, 2017 through June 30, 2017, the period for which Pharmchem was owned.
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
Unaudited pro forma information
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions, except per share amounts)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Sales
|
$
|
943
|
|
|
$
|
861
|
|
|
$
|
2,589
|
|
|
$
|
2,485
|
|
|
Net income (loss)
|
(26
|
)
|
|
70
|
|
|
97
|
|
|
245
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Income (loss) from discontinued operations (net of tax)
|
|
|
|
|
|
|
|
||||||||
|
Asbestos-related litigation
|
$
|
(25
|
)
|
|
$
|
(30
|
)
|
|
$
|
(25
|
)
|
|
$
|
(30
|
)
|
|
Water Technologies
|
(1
|
)
|
|
3
|
|
|
2
|
|
|
2
|
|
||||
|
Valvoline
|
12
|
|
|
73
|
|
|
161
|
|
|
214
|
|
||||
|
Gain on disposal of discontinued operations (net of tax)
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Water Technologies
|
—
|
|
|
1
|
|
|
—
|
|
|
—
|
|
||||
|
Total income (loss) from discontinued operations (net of tax)
|
$
|
(14
|
)
|
|
$
|
47
|
|
|
$
|
138
|
|
|
$
|
186
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
(a)
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Income (loss) from discontinued operations
|
|
|
|
|
|
|
|
||||||||
|
attributable to Valvoline
|
|
|
|
|
|
|
|
||||||||
|
Sales
|
$
|
234
|
|
|
$
|
500
|
|
|
$
|
1,237
|
|
|
$
|
1,435
|
|
|
Cost of sales
|
(148
|
)
|
|
(300
|
)
|
|
(750
|
)
|
|
(868
|
)
|
||||
|
Selling, general and administrative expense
|
(50
|
)
|
|
(84
|
)
|
|
(222
|
)
|
|
(245
|
)
|
||||
|
Research and development expense
|
(1
|
)
|
|
(3
|
)
|
|
(8
|
)
|
|
(9
|
)
|
||||
|
Equity and other income
|
3
|
|
|
5
|
|
|
17
|
|
|
16
|
|
||||
|
Operating income of discontinued operations
|
38
|
|
|
118
|
|
|
274
|
|
|
329
|
|
||||
|
Net interest and other financing expense
|
(5
|
)
|
|
—
|
|
|
(22
|
)
|
|
—
|
|
||||
|
Pretax income of discontinued operations
|
33
|
|
|
118
|
|
|
252
|
|
|
329
|
|
||||
|
Income tax expense
|
(21
|
)
|
|
(45
|
)
|
|
(91
|
)
|
|
(115
|
)
|
||||
|
Income from discontinued operations
|
$
|
12
|
|
|
$
|
73
|
|
|
$
|
161
|
|
|
$
|
214
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
(a)
|
Valvoline results in the current quarter reflect only 42 days of activity since the business was fully distributed on May 12, 2017.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30
|
|
|
|
(In millions)
|
2016
|
|
|
|
Cash
|
$
|
171
|
|
|
Accounts receivable, net
|
387
|
|
|
|
Inventories
|
131
|
|
|
|
Other current assets
|
25
|
|
|
|
Current assets of discontinued operations
|
$
|
714
|
|
|
|
|
||
|
Net property, plant and equipment
|
$
|
324
|
|
|
Goodwill
|
264
|
|
|
|
Equity and other unconsolidated investments
|
26
|
|
|
|
Deferred income taxes
|
347
|
|
|
|
Other noncurrent assets
|
92
|
|
|
|
Noncurrent assets of discontinued operations
|
$
|
1,053
|
|
|
|
|
||
|
Current portion of long-term debt
|
$
|
19
|
|
|
Trade and other payables
|
360
|
|
|
|
Current liabilities of discontinued operations
|
$
|
379
|
|
|
|
|
||
|
Long-term debt
|
$
|
730
|
|
|
Employee benefit obligations
|
886
|
|
|
|
Other long-term liabilities
|
99
|
|
|
|
Noncurrent liabilities of discontinued operations
|
$
|
1,715
|
|
|
|
|
||
|
Equity
|
|
||
|
Noncontrolling interest
|
$
|
(182
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In millions)
|
Carrying
value
|
|
|
Total
fair
value
|
|
|
Quoted prices
in active
markets for
identical
assets
Level 1
|
|
|
Significant
other
observable
inputs
Level 2
|
|
|
Significant
unobservable
inputs
Level 3
|
|
|||||
|
Assets
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Cash and cash equivalents
|
$
|
492
|
|
|
$
|
492
|
|
|
$
|
492
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Restricted investments
(a)
|
329
|
|
|
329
|
|
|
329
|
|
|
—
|
|
|
—
|
|
|||||
|
Deferred compensation investments
(b)
|
155
|
|
|
155
|
|
|
—
|
|
|
155
|
|
|
—
|
|
|||||
|
Investments of captive insurance company
(b)
|
3
|
|
|
3
|
|
|
3
|
|
|
—
|
|
|
—
|
|
|||||
|
Foreign currency derivatives
|
14
|
|
|
14
|
|
|
—
|
|
|
14
|
|
|
—
|
|
|||||
|
Total assets at fair value
|
$
|
993
|
|
|
$
|
993
|
|
|
$
|
824
|
|
|
$
|
169
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Foreign currency derivatives
|
$
|
10
|
|
|
$
|
10
|
|
|
$
|
—
|
|
|
$
|
10
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
(a)
|
Included in restricted investments and
$30 million
within other current assets in the Condensed Consolidated Balance Sheets.
|
|
(b)
|
Included in other noncurrent assets in the Condensed Consolidated Balance Sheets.
|
|
(In millions)
|
Carrying
value
|
|
|
Total
fair
value
|
|
|
Quoted prices
in active
markets for
identical
assets
Level 1
|
|
|
Significant
other
observable
inputs
Level 2
|
|
|
Significant
unobservable
inputs
Level 3
|
|
|||||
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Cash and cash equivalents
|
$
|
1,017
|
|
|
$
|
1,017
|
|
|
$
|
1,017
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Restricted investments
(a)
|
322
|
|
|
322
|
|
|
322
|
|
|
—
|
|
|
—
|
|
|||||
|
Deferred compensation investments
(b)
|
150
|
|
|
150
|
|
|
—
|
|
|
150
|
|
|
—
|
|
|||||
|
Investments of captive insurance company
(b)
|
4
|
|
|
4
|
|
|
4
|
|
|
—
|
|
|
—
|
|
|||||
|
Foreign currency derivatives
|
3
|
|
|
3
|
|
|
—
|
|
|
3
|
|
|
—
|
|
|||||
|
Total assets at fair value
|
$
|
1,496
|
|
|
$
|
1,496
|
|
|
$
|
1,343
|
|
|
$
|
153
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Foreign currency derivatives
|
$
|
5
|
|
|
$
|
5
|
|
|
$
|
—
|
|
|
$
|
5
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
(a)
|
Included in restricted investments and
$30 million
within other current assets in the Condensed Consolidated Balance Sheets.
|
|
(b)
|
Included in other noncurrent assets in the Condensed Consolidated Balance Sheets.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30
|
|
|
September 30
|
|
||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Original cost
|
$
|
335
|
|
|
$
|
335
|
|
|
Accumulated investment income, settlement funds
|
|
|
|
||||
|
and disbursements, net
|
(24
|
)
|
|
(3
|
)
|
||
|
Adjusted cost
(a)
|
311
|
|
|
332
|
|
||
|
Investment income
(b)
|
7
|
|
|
8
|
|
||
|
Unrealized gain
|
26
|
|
|
11
|
|
||
|
Realized gain
|
2
|
|
|
—
|
|
||
|
Settlement funds
|
2
|
|
|
4
|
|
||
|
Disbursements
|
(19
|
)
|
|
(33
|
)
|
||
|
Fair value
|
$
|
329
|
|
|
$
|
322
|
|
|
|
|
|
|
||||
|
(a)
|
The adjusted cost of the demand deposit includes accumulated investment income, disbursements and settlements recorded in previous periods.
|
|
(b)
|
Investment income for the demand deposit includes interest income as well as dividend income transferred from the equity and corporate bond mutual funds.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
|
|
|
Gross
|
|
|
|
||||||
|
(In millions)
|
Adjusted Cost
|
|
|
Unrealized Gain
|
|
|
Unrealized Loss
|
|
|
Fair Value
|
|
||||
|
As of June 30, 2017
|
|
|
|
|
|
|
|
||||||||
|
Demand Deposit
|
$
|
15
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
15
|
|
|
Equity Mutual Fund
|
168
|
|
|
26
|
|
|
—
|
|
|
194
|
|
||||
|
Corporate bond Mutual Fund
|
120
|
|
|
—
|
|
|
—
|
|
|
120
|
|
||||
|
Fair value
|
$
|
303
|
|
|
$
|
26
|
|
|
$
|
—
|
|
|
$
|
329
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
As of September 30, 2016
|
|
|
|
|
|
|
|
||||||||
|
Demand Deposit
|
$
|
6
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
6
|
|
|
Equity Mutual Fund
|
185
|
|
|
8
|
|
|
—
|
|
|
193
|
|
||||
|
Corporate bond Mutual Fund
|
120
|
|
|
3
|
|
|
—
|
|
|
123
|
|
||||
|
Fair value
|
$
|
311
|
|
|
$
|
11
|
|
|
$
|
—
|
|
|
$
|
322
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Investment income
|
$
|
2
|
|
|
$
|
2
|
|
|
$
|
7
|
|
|
$
|
6
|
|
|
Realized gains
|
—
|
|
|
—
|
|
|
2
|
|
|
—
|
|
||||
|
Disbursements
|
(7
|
)
|
|
(1
|
)
|
|
(19
|
)
|
|
(24
|
)
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Foreign currency derivative gain (loss)
|
$
|
(1
|
)
|
|
$
|
(3
|
)
|
|
$
|
10
|
|
|
$
|
1
|
|
|
|
June 30
|
|
|
September 30
|
|
||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Foreign currency derivative assets
|
$
|
14
|
|
|
$
|
3
|
|
|
Notional contract values
|
842
|
|
|
325
|
|
||
|
|
|
|
|
||||
|
Foreign currency derivative liabilities
|
$
|
10
|
|
|
$
|
4
|
|
|
Notional contract values
|
797
|
|
|
528
|
|
||
|
|
|
June 30
|
|
|
September 30
|
|
||
|
(In millions)
|
Consolidated balance sheet caption
|
2017
|
|
|
2016
|
|
||
|
Net investment hedge assets
(a)
|
Accounts receivable
|
$
|
—
|
|
|
$
|
—
|
|
|
Net investment hedge liabilities
(a)
|
Accrued expenses and other liabilities
|
—
|
|
|
1
|
|
||
|
|
|
|
|
|
||||
|
(a)
|
Fair value of $0 denotes a value less than $1 million.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Change in unrealized gain in AOCI
(a)
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Tax impact of change in unrealized gain in AOCI
(a)
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
(a)
|
$0 denotes a value less than $1 million.
|
|
|
June 30
|
|
|
September 30
|
|
||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Finished products
|
$
|
381
|
|
|
$
|
377
|
|
|
Raw materials, supplies and work in process
|
251
|
|
|
163
|
|
||
|
LIFO reserves
|
(1
|
)
|
|
(1
|
)
|
||
|
|
$
|
631
|
|
|
$
|
539
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Specialty
|
|
|
|
|
Intermediates
|
|
|
|
|
|||||
|
(In millions)
|
Ingredients
|
|
|
Composites
|
|
|
and Solvents
|
|
|
Total
|
|
||||
|
Balance as of September 30, 2016
|
$
|
1,991
|
|
|
$
|
147
|
|
|
$
|
—
|
|
|
$
|
2,138
|
|
|
Acquisitions
(a)
|
276
|
|
|
—
|
|
|
—
|
|
|
276
|
|
||||
|
Currency translation adjustment
|
12
|
|
|
—
|
|
|
—
|
|
|
12
|
|
||||
|
Balance as of June 30, 2017
|
$
|
2,279
|
|
|
$
|
147
|
|
|
$
|
—
|
|
|
$
|
2,426
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
(a)
|
Relates to the acquisition of Pharmachem during the current quarter. See Note C for more information.
|
|
|
June 30, 2017
|
||||||||||
|
|
Gross
|
|
|
|
|
Net
|
|
||||
|
|
carrying
|
|
|
Accumulated
|
|
|
carrying
|
|
|||
|
(In millions)
|
amount
|
|
|
amortization
|
|
|
amount
|
|
|||
|
Definite-lived intangible assets
|
|
|
|
|
|
||||||
|
Trademarks and trade names
|
$
|
66
|
|
|
$
|
(21
|
)
|
|
$
|
45
|
|
|
Intellectual property
|
735
|
|
|
(308
|
)
|
|
427
|
|
|||
|
Customer and supplier relationships
|
759
|
|
|
(216
|
)
|
|
543
|
|
|||
|
Total definite-lived intangible assets
(a)
|
1,560
|
|
|
(545
|
)
|
|
1,015
|
|
|||
|
|
|
|
|
|
|
||||||
|
Indefinite-lived intangible assets
|
|
|
|
|
|
||||||
|
Trademarks and trade names
|
301
|
|
|
—
|
|
|
301
|
|
|||
|
Total intangible assets
|
$
|
1,861
|
|
|
$
|
(545
|
)
|
|
$
|
1,316
|
|
|
|
|
|
|
|
|
||||||
|
(a)
|
The gross carrying amount of the definite-lived intangible assets increased during the nine months ended
June 30, 2017
primarily due to the acquisition of Pharmachem. See Note C for more information.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2016
|
||||||||||
|
|
Gross
|
|
|
|
|
Net
|
|
||||
|
|
carrying
|
|
|
Accumulated
|
|
|
carrying
|
|
|||
|
(In millions)
|
amount
|
|
|
amortization
|
|
|
amount
|
|
|||
|
Definite-lived intangible assets
|
|
|
|
|
|
||||||
|
Trademarks and trade names
|
$
|
40
|
|
|
$
|
(19
|
)
|
|
$
|
21
|
|
|
Intellectual property
|
667
|
|
|
(273
|
)
|
|
394
|
|
|||
|
Customer relationships
|
543
|
|
|
(198
|
)
|
|
345
|
|
|||
|
Total definite-lived intangible assets
|
1,250
|
|
|
(490
|
)
|
|
760
|
|
|||
|
|
|
|
|
|
|
||||||
|
Indefinite-lived intangible assets
|
|
|
|
|
|
||||||
|
Trademarks and trade names
|
301
|
|
|
—
|
|
|
301
|
|
|||
|
Total intangible assets
|
$
|
1,551
|
|
|
$
|
(490
|
)
|
|
$
|
1,061
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30
|
|
|
September 30
|
|
||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
4.750% notes, due 2022
|
1,082
|
|
|
1,121
|
|
||
|
Term Loan B, due 2024
|
600
|
|
|
—
|
|
||
|
6.875% notes, due 2043
|
376
|
|
|
376
|
|
||
|
Term Loan A, due 2022
|
250
|
|
|
—
|
|
||
|
Term Loan A, due 2020
|
250
|
|
|
—
|
|
||
|
Revolving Credit Facility
|
128
|
|
|
—
|
|
||
|
Accounts receivable securitization
|
95
|
|
|
—
|
|
||
|
6.50% junior subordinated notes, due 2029
|
51
|
|
|
140
|
|
||
|
Other international loans
|
—
|
|
|
20
|
|
||
|
Medium-term notes, due 2019, interest of 9.4% at June 30, 2017
|
5
|
|
|
5
|
|
||
|
Term Loan, due 2017
|
—
|
|
|
150
|
|
||
|
3.875% notes, due 2018
|
—
|
|
|
700
|
|
||
|
Other
(a)
|
(24
|
)
|
|
(17
|
)
|
||
|
Total debt
|
2,813
|
|
|
2,495
|
|
||
|
Short-term debt
|
(223
|
)
|
|
(170
|
)
|
||
|
Current portion of long-term debt
|
(6
|
)
|
|
—
|
|
||
|
Long-term debt (less current portion and debt issuance cost discounts)
|
$
|
2,584
|
|
|
$
|
2,325
|
|
|
|
|
|
|
||||
|
(a)
|
Other includes
$26 million
and
$20 million
of debt issuance cost discounts as of
June 30, 2017
and
September 30, 2016
, respectively.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In millions)
|
|
|
|
|
Balance at October 1, 2016
|
$
|
168
|
|
|
Increases related to positions taken on items from prior years
|
6
|
|
|
|
Decreases related to positions taken on items from prior years
|
(2
|
)
|
|
|
Increases related to positions taken in the current year
|
12
|
|
|
|
Pharmachem acquisition
|
12
|
|
|
|
Lapse of the statute of limitations
|
(3
|
)
|
|
|
Settlement of uncertain tax positions with tax authorities
|
(1
|
)
|
|
|
Balance at June 30, 2017
|
$
|
192
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
As a result of the remeasurement of the affected U.S. pension plans, Ashland recognized a curtailment gain of
$65 million
and actuarial loss of
$123 million
during the
nine
months ended
June 30, 2016
. Of these amounts,
$12 million
of the curtailment gain and
$22 million
of the actuarial loss were attributable to Valvoline and are included within the discontinued operations caption of the Statements of Consolidated Comprehensive Income.
|
|
•
|
As a result of the remeasurement of other postretirement benefit plans, Ashland recognized a curtailment gain of
$39 million
and actuarial loss of
$7 million
during the
nine
months ended
June 30, 2016
. Of these amounts,
$6 million
of the curtailment gain and
$1 million
of the actuarial loss were attributable to Valvoline and are included within the discontinued operations caption of the Statements of Consolidated Comprehensive Income. This remeasurement reduced the benefit obligations by
$86 million
.
|
|
•
|
Ashland was also required to remeasure a non-U.S. pension plan during the prior year quarter and as a result recognized a curtailment gain of
$6 million
and actuarial loss of
$3 million
during the
nine
months ended
June 30, 2016
.
|
|
|
|
|
|
|
Other postretirement
|
||||||||||
|
|
Pension benefits
|
|
benefits
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Three months ended June 30
|
|
|
|
|
|
|
|
||||||||
|
Service cost
(a)
|
$
|
3
|
|
|
$
|
7
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Interest cost
|
12
|
|
|
27
|
|
|
—
|
|
|
1
|
|
||||
|
Expected return on plan assets
|
(19
|
)
|
|
(46
|
)
|
|
—
|
|
|
—
|
|
||||
|
Amortization of prior service credit
(a)
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
(3
|
)
|
||||
|
|
$
|
(4
|
)
|
|
$
|
(12
|
)
|
|
$
|
(1
|
)
|
|
$
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
||||||||
|
Nine months ended June 30
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Service cost
(a)
|
$
|
8
|
|
|
$
|
20
|
|
|
$
|
—
|
|
|
$
|
1
|
|
|
Interest cost
|
59
|
|
|
89
|
|
|
2
|
|
|
3
|
|
||||
|
Expected return on plan assets
|
(97
|
)
|
|
(141
|
)
|
|
—
|
|
|
—
|
|
||||
|
Amortization of prior service credit
(a)
|
—
|
|
|
(1
|
)
|
|
(7
|
)
|
|
(11
|
)
|
||||
|
Curtailment gain
|
—
|
|
|
(71
|
)
|
|
—
|
|
|
(39
|
)
|
||||
|
Actuarial (gain) loss
|
—
|
|
|
126
|
|
|
(10
|
)
|
|
7
|
|
||||
|
|
$
|
(30
|
)
|
|
$
|
22
|
|
|
$
|
(15
|
)
|
|
$
|
(39
|
)
|
|
|
|
|
|
|
|
|
|
||||||||
|
(a)
|
Activity of $0 denote values less than $1 million.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
|
|
|
|
|
|
|||||||
|
|
June 30
|
|
Years ended September 30
|
|||||||||||
|
(In thousands)
|
2017
|
|
|
2016
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|
Open claims - beginning of period
|
57
|
|
|
60
|
|
|
60
|
|
|
65
|
|
|
65
|
|
|
New claims filed
|
2
|
|
|
2
|
|
|
2
|
|
|
2
|
|
|
2
|
|
|
Claims settled
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
Claims dismissed
|
(3
|
)
|
|
(4
|
)
|
|
(5
|
)
|
|
(7
|
)
|
|
(1
|
)
|
|
Open claims - end of period
|
55
|
|
|
58
|
|
|
57
|
|
|
60
|
|
|
65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
|
|
|
|
|
|
||||||||||||
|
|
June 30
|
|
Years ended September 30
|
||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|||||
|
Asbestos reserve - beginning of period
|
$
|
415
|
|
|
$
|
409
|
|
|
$
|
409
|
|
|
$
|
438
|
|
|
$
|
463
|
|
|
Reserve adjustment
|
36
|
|
|
37
|
|
|
37
|
|
|
—
|
|
|
4
|
|
|||||
|
Amounts paid
|
(27
|
)
|
|
(27
|
)
|
|
(31
|
)
|
|
(29
|
)
|
|
(29
|
)
|
|||||
|
Asbestos reserve - end of period
|
$
|
424
|
|
|
$
|
419
|
|
|
$
|
415
|
|
|
$
|
409
|
|
|
$
|
438
|
|
|
|
Nine months ended
|
|
|
|
|
|
|
||||||||||||
|
|
June 30
|
|
Years ended September 30
|
||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|||||
|
Insurance receivable - beginning of period
|
$
|
151
|
|
|
$
|
150
|
|
|
$
|
150
|
|
|
$
|
402
|
|
|
$
|
408
|
|
|
Receivable adjustment
|
15
|
|
|
16
|
|
|
16
|
|
|
(3
|
)
|
|
22
|
|
|||||
|
Insurance settlement
|
(5
|
)
|
|
(4
|
)
|
|
(4
|
)
|
|
(227
|
)
|
|
—
|
|
|||||
|
Amounts collected
|
(5
|
)
|
|
(10
|
)
|
|
(11
|
)
|
|
(22
|
)
|
|
(28
|
)
|
|||||
|
Insurance receivable - end of period
|
$
|
156
|
|
|
$
|
152
|
|
|
$
|
151
|
|
|
$
|
150
|
|
|
$
|
402
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
|
|
|
|
|
|
|||||||
|
|
June 30
|
|
Years ended September 30
|
|||||||||||
|
(In thousands)
|
2017
|
|
|
2016
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|
Open claims - beginning of period
|
15
|
|
|
20
|
|
|
20
|
|
|
21
|
|
|
21
|
|
|
New claims filed
|
1
|
|
|
1
|
|
|
1
|
|
|
1
|
|
|
1
|
|
|
Claims dismissed
|
(4
|
)
|
|
(5
|
)
|
|
(6
|
)
|
|
(2
|
)
|
|
(1
|
)
|
|
Open claims - end of period
|
12
|
|
|
16
|
|
|
15
|
|
|
20
|
|
|
21
|
|
|
|
Nine months ended
|
|
|
|
|
|
|
||||||||||||
|
|
June 30
|
|
Years ended September 30
|
||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|||||
|
Asbestos reserve - beginning of period
|
$
|
321
|
|
|
$
|
311
|
|
|
$
|
311
|
|
|
$
|
329
|
|
|
$
|
342
|
|
|
Reserve adjustment
|
16
|
|
|
25
|
|
|
25
|
|
|
4
|
|
|
10
|
|
|||||
|
Amounts paid
|
(9
|
)
|
|
(10
|
)
|
|
(15
|
)
|
|
(22
|
)
|
|
(23
|
)
|
|||||
|
Asbestos reserve - end of period
|
$
|
328
|
|
|
$
|
326
|
|
|
$
|
321
|
|
|
$
|
311
|
|
|
$
|
329
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
|
|
|
|
|
|
||||||||||||
|
|
June 30
|
|
Years ended September 30
|
||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2016
|
|
|
2015
|
|
|
2014
|
|
|||||
|
Insurance receivable - beginning of period
|
$
|
63
|
|
|
$
|
56
|
|
|
$
|
56
|
|
|
$
|
77
|
|
|
$
|
75
|
|
|
Receivable adjustment
|
5
|
|
|
7
|
|
|
7
|
|
|
1
|
|
|
3
|
|
|||||
|
Insurance settlement
|
—
|
|
|
—
|
|
|
—
|
|
|
(22
|
)
|
|
—
|
|
|||||
|
Amounts collected
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
|||||
|
Insurance receivable - end of period
|
$
|
68
|
|
|
$
|
63
|
|
|
$
|
63
|
|
|
$
|
56
|
|
|
$
|
77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
||||||
|
|
June 30
|
||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Reserve - beginning of period
|
$
|
177
|
|
|
$
|
186
|
|
|
Disbursements
|
(22
|
)
|
|
(32
|
)
|
||
|
Revised obligation estimates and accretion
|
18
|
|
|
32
|
|
||
|
Reserve - end of period
|
$
|
173
|
|
|
$
|
186
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Environmental expense
|
$
|
11
|
|
|
$
|
17
|
|
|
$
|
16
|
|
|
$
|
30
|
|
|
Accretion
|
2
|
|
|
1
|
|
|
2
|
|
|
2
|
|
||||
|
Legal expense
|
1
|
|
|
1
|
|
|
6
|
|
|
6
|
|
||||
|
Total expense
|
14
|
|
|
19
|
|
|
24
|
|
|
38
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Insurance receivable
|
(2
|
)
|
|
(2
|
)
|
|
(2
|
)
|
|
(3
|
)
|
||||
|
Total expense, net of receivable activity
(a)
|
$
|
12
|
|
|
$
|
17
|
|
|
$
|
22
|
|
|
$
|
35
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
(a)
|
Net expense of
$1 million
and
$3 million
for the three and
nine
months ended
June 30, 2017
, respectively, and
$1 million
and
$2 million
for the three and
nine
months ended
June 30, 2016
, respectively, relates to divested businesses which qualified for treatment as discontinued operations and for which certain environmental liabilities were retained by Ashland. These amounts are classified within the income (loss) from discontinued operations caption of the Statements of Consolidated Comprehensive Income.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions except per share data)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Numerator
|
|
|
|
|
|
|
|
||||||||
|
Numerator for basic and diluted EPS –
|
|
|
|
|
|
|
|
||||||||
|
Income (loss) from continuing operations
|
$
|
(16
|
)
|
|
$
|
24
|
|
|
$
|
(53
|
)
|
|
$
|
61
|
|
|
Denominator
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Denominator for basic EPS – Weighted-average
|
|
|
|
|
|
|
|
|
|
|
|||||
|
common shares outstanding
|
62
|
|
|
62
|
|
|
62
|
|
|
63
|
|
||||
|
Share-based awards convertible to common shares
(a)
|
—
|
|
|
1
|
|
|
—
|
|
|
1
|
|
||||
|
Denominator for diluted EPS – Adjusted weighted-
|
|
|
|
|
|
|
|
|
|
|
|||||
|
average shares and assumed conversions
|
62
|
|
|
63
|
|
|
62
|
|
|
64
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
EPS from continuing operations attributable
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
to Ashland
|
|
|
|
|
|
|
|
||||||||
|
Basic
|
$
|
(0.26
|
)
|
|
$
|
0.39
|
|
|
$
|
(0.85
|
)
|
|
$
|
0.97
|
|
|
Diluted
|
(0.26
|
)
|
|
0.38
|
|
|
(0.85
|
)
|
|
0.95
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
(a)
|
As a result of the loss from continuing operations attributable to Ashland during the three and nine months ended
June 30, 2017
, the effect of the share-based awards convertible to common shares would be antidilutive. As such, they have been excluded from the diluted EPS calculation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017
|
|
2016
|
||||||||||||||||||||
|
|
|
|
Tax
|
|
|
|
|
|
|
Tax
|
|
|
|
||||||||||
|
|
Before
|
|
|
(expense)
|
|
|
Net of
|
|
|
Before
|
|
|
(expense)
|
|
|
Net of
|
|
||||||
|
(In millions)
|
tax
|
|
|
benefit
|
|
|
tax
|
|
|
tax
|
|
|
benefit
|
|
|
tax
|
|
||||||
|
Three months ended June 30
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Other comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Unrealized translation gain (loss)
|
$
|
107
|
|
|
$
|
(2
|
)
|
|
$
|
105
|
|
|
$
|
(45
|
)
|
|
$
|
(1
|
)
|
|
$
|
(46
|
)
|
|
Pension and postretirement obligation adjustment:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Amortization of unrecognized prior service
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
credits included in net income
(a)
|
(1
|
)
|
|
1
|
|
|
—
|
|
|
(3
|
)
|
|
3
|
|
|
—
|
|
||||||
|
Net change in available-for-sale securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Unrealized gain during period
|
6
|
|
|
(2
|
)
|
|
4
|
|
|
7
|
|
|
(3
|
)
|
|
4
|
|
||||||
|
Total other comprehensive income (loss)
|
$
|
112
|
|
|
$
|
(3
|
)
|
|
$
|
109
|
|
|
$
|
(41
|
)
|
|
$
|
(1
|
)
|
|
$
|
(42
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Nine months ended June 30
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Other comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Unrealized translation gain (loss)
|
$
|
15
|
|
|
$
|
4
|
|
|
$
|
19
|
|
|
$
|
(27
|
)
|
|
$
|
1
|
|
|
$
|
(26
|
)
|
|
Pension and postretirement obligation adjustment:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Adjustment of unrecognized prior service credit
|
—
|
|
|
—
|
|
|
—
|
|
|
86
|
|
|
(31
|
)
|
|
55
|
|
||||||
|
Amortization of unrecognized prior service
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
credits included in net income
(a)
|
(7
|
)
|
|
3
|
|
|
(4
|
)
|
|
(52
|
)
|
|
18
|
|
|
(34
|
)
|
||||||
|
Net change in available-for-sale securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Unrealized gain during period
|
15
|
|
|
(4
|
)
|
|
11
|
|
|
21
|
|
|
(8
|
)
|
|
13
|
|
||||||
|
Reclassification adjustment for gains
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
included in net income
|
(2
|
)
|
|
1
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Total other comprehensive income
|
$
|
21
|
|
|
$
|
4
|
|
|
$
|
25
|
|
|
$
|
28
|
|
|
$
|
(20
|
)
|
|
$
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
(a)
|
Amortization of unrecognized prior service credits are included in the calculation of net periodic benefit costs (income) for pension and other postretirement plans. For specific financial statement captions impacted by the amortization see the table below.
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Cost of sales
|
$
|
—
|
|
|
$
|
(1
|
)
|
|
$
|
—
|
|
|
$
|
(18
|
)
|
|
Selling, general and administrative expense
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
(26
|
)
|
||||
|
Discontinued operations
|
(1
|
)
|
|
(1
|
)
|
|
(7
|
)
|
|
(8
|
)
|
||||
|
Total amortization of unrecognized prior service credits
|
$
|
(1
|
)
|
|
$
|
(3
|
)
|
|
$
|
(7
|
)
|
|
$
|
(52
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions - unaudited)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
SALES
|
|
|
|
|
|
|
|
||||||||
|
Specialty Ingredients
|
$
|
591
|
|
|
$
|
552
|
|
|
$
|
1,617
|
|
|
$
|
1,557
|
|
|
Composites
|
209
|
|
|
174
|
|
|
561
|
|
|
508
|
|
||||
|
Intermediates and Solvents
|
70
|
|
|
64
|
|
|
202
|
|
|
200
|
|
||||
|
|
$
|
870
|
|
|
$
|
790
|
|
|
$
|
2,380
|
|
|
$
|
2,265
|
|
|
OPERATING INCOME (LOSS)
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Specialty Ingredients
|
$
|
58
|
|
|
$
|
66
|
|
|
$
|
172
|
|
|
$
|
169
|
|
|
Composites
|
22
|
|
|
17
|
|
|
50
|
|
|
55
|
|
||||
|
Intermediates and Solvents
|
2
|
|
|
(1
|
)
|
|
(8
|
)
|
|
5
|
|
||||
|
Unallocated and other
|
(45
|
)
|
|
(25
|
)
|
|
(106
|
)
|
|
(85
|
)
|
||||
|
|
$
|
37
|
|
|
$
|
57
|
|
|
$
|
108
|
|
|
$
|
144
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||
|
|
June 30
|
|
June 30
|
||||||||
|
Sales by Geography
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
North America
(a)
|
41
|
%
|
|
40
|
%
|
|
40
|
%
|
|
39
|
%
|
|
Europe
|
33
|
%
|
|
34
|
%
|
|
32
|
%
|
|
34
|
%
|
|
Asia Pacific
|
18
|
%
|
|
18
|
%
|
|
19
|
%
|
|
18
|
%
|
|
Latin America & other
|
8
|
%
|
|
8
|
%
|
|
9
|
%
|
|
9
|
%
|
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three months ended
|
|
Nine months ended
|
||||||||
|
|
June 30
|
|
June 30
|
||||||||
|
Sales by Reportable Segment
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
Specialty Ingredients
|
68
|
%
|
|
70
|
%
|
|
68
|
%
|
|
69
|
%
|
|
Composites
|
24
|
%
|
|
22
|
%
|
|
24
|
%
|
|
22
|
%
|
|
Intermediates and Solvents
|
8
|
%
|
|
8
|
%
|
|
8
|
%
|
|
9
|
%
|
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
EBITDA - net income, plus income tax expense (benefit), net interest and other financing expenses, and depreciation and amortization.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
Adjusted EBITDA - EBITDA adjusted for noncontrolling interests, discontinued operations, net gain (loss) on acquisitions and divestitures, other income and (expense) and key items (including the remeasurement gains and losses related to pension and other postretirement plans).
|
|
•
|
Adjusted EBITDA margin - Adjusted EBITDA divided by sales.
|
|
•
|
Free cash flow - operating cash flows less capital expenditures and certain other adjustments as applicable.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
Ashland’s net income (loss) attributable to Ashland amounted to a loss of
$33 million
and income of
$71 million
for the three months ended
June 30, 2017
and
2016
, respectively, or a loss of
$0.54
and income of
$1.13
diluted earnings per share, respectively.
|
|
•
|
Ashland’s net income attributable to noncontrolling interest amounted to
$3 million
for the three months ended
June 30, 2017
and reflects the noncontrolling interest of Valvoline Inc. before the final distribution occurred on May 12, 2017.
|
|
•
|
Discontinued operations, which are reported net of taxes, resulted in a loss of
$14 million
and income of
$47 million
during three months ended
June 30, 2017
and
2016
, respectively. The activity within discontinued operations primarily includes the results of Valvoline Inc. and updates to the asbestos liability and receivable models.
|
|
•
|
Income (loss) from continuing operations, which excludes results from discontinued operations, amounted to a loss of
$16 million
and income of
$24 million
for the three months ended
June 30, 2017
and
2016
, respectively.
|
|
•
|
The effective income tax rate was
20%
and a benefit of
20%
for the three months ended
June 30, 2017
and
2016
, and was impacted by certain discrete items in both the current and prior year quarters.
|
|
•
|
Ashland incurred pretax net interest and other financing expense of
$51 million
and
$40 million
for the three months ended
June 30, 2017
and
2016
, respectively.
|
|
•
|
Operating income was
$37 million
and
$57 million
for the three months ended
June 30, 2017
and
2016
, respectively.
|
|
•
|
Ashland’s net income attributable to Ashland amounted to
$58 million
and
$247 million
for the
nine
months ended
June 30, 2017
and
2016
, respectively, or
$0.93
and
$3.87
diluted earnings per share, respectively.
|
|
•
|
Ashland’s net income attributable to noncontrolling interest amounted to
$27 million
for the
nine
months ended
June 30, 2017
and reflects the noncontrolling interest of Valvoline Inc. before the final distribution occurred on May 12, 2017.
|
|
•
|
Discontinued operations, which are reported net of taxes, resulted in income of
$138 million
and
$186 million
during the
nine
months ended
June 30, 2017
and
2016
, respectively. The activity within
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
Income (loss) from continuing operations, which excludes results from discontinued operations, amounted to a loss of
$53 million
and income of
$61 million
for the
nine
months ended
June 30, 2017
and
2016
, respectively.
|
|
•
|
The effective income tax rate was
48%
and a benefit of
177%
for the
nine
months ended
June 30, 2017
and
2016
, respectively, and was impacted by certain discrete items in both the current and prior year periods.
|
|
•
|
Ashland incurred pretax net interest and other financing expense of
$203 million
and
$125 million
for the
nine
months ended
June 30, 2017
and
2016
, respectively. The current period was impacted by $92 million of net charges associated with current period debt financing activity.
|
|
•
|
Operating income was
$108 million
and
$144 million
for the
nine
months ended
June 30, 2017
and
2016
, respectively.
|
|
◦
|
$28 million
of costs related to the separation of Valvoline during each of the three months ended
June 30, 2017
and
2016
(which included $1 million of accelerated depreciation during the three months ended
June 30, 2016
);
|
|
◦
|
$13 million of restructuring charges for a plant closure during the three months ended
June 30, 2017
(which included $11 million of accelerated depreciation);
|
|
◦
|
$1 million of integration costs related to the acquisition of Pharmachem for the three months ended
June 30, 2017
;
|
|
◦
|
$4 million of restructuring charges related to the exit from a toller agreement and restructuring of a manufacturing facility during the three months ended
June 30, 2016
;
|
|
•
|
$9 million and $15 million of environmental reserve charges related to previously divested businesses during the three months ended
June 30, 2017
and
2016
, respectively;
|
|
•
|
$6 million of a net loss on acquisitions and divestitures during the three months ended
June 30, 2017
;
|
|
•
|
$1 million
of noncash charges related to the fair value assessment of inventory acquired from Pharmachem at the date of acquisition; and
|
|
•
|
$11 million and $5 million of income related to a legacy benefit for former directors and a customer claim adjustment, respectively, during the three months ended
June 30, 2016
.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
|
June 30
|
||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Net income (loss)
|
$
|
(30
|
)
|
|
$
|
71
|
|
|
Income tax benefit
|
(4
|
)
|
|
(4
|
)
|
||
|
Net interest and other financing expense
|
51
|
|
|
40
|
|
||
|
Depreciation and amortization
(a)
|
72
|
|
|
76
|
|
||
|
EBITDA
|
89
|
|
|
183
|
|
||
|
Loss (income) from discontinued operations (net of tax)
|
14
|
|
|
(47
|
)
|
||
|
Separation, restructuring and other costs, net
|
31
|
|
|
31
|
|
||
|
Environmental reserve adjustment
|
9
|
|
|
15
|
|
||
|
Benefit adjustment
|
—
|
|
|
(11
|
)
|
||
|
Customer claim adjustment
|
—
|
|
|
(5
|
)
|
||
|
Accelerated depreciation
|
11
|
|
|
1
|
|
||
|
Net loss on acquisitions and divestitures
|
6
|
|
|
—
|
|
||
|
Inventory fair value adjustment
|
1
|
|
|
—
|
|
||
|
Adjusted EBITDA
(b)
|
$
|
161
|
|
|
$
|
167
|
|
|
|
|
|
|
||||
|
(a)
|
Excludes
$11 million
and
$1 million
of accelerated depreciation
three
months ended
June 30, 2017
and
2016
, respectively.
|
|
(b)
|
Includes $3 million of expense and
$12 million
of income during the
three
months ended
June 30, 2017
and
2016
, respectively, related to net periodic pension and other postretirement costs (income) recognized ratably through the fiscal year. These amounts are comprised of service cost, interest cost, expected return on plan assets, and amortization of prior service credit and is disclosed in further detail in Note J of the Notes to Condensed Consolidated Financial Statements.
|
|
◦
|
an additional $41 million, including $1 million of accelerated depreciation, and $18 million of costs related to the separation of Valvoline during the
nine
months ended
June 30, 2017
and
2016
, respectively;
|
|
◦
|
additional adjustments related to a restructuring plan within an existing manufacturing facility of a $5 million reversal of the previous severance accrual and $4 million of accelerated depreciation during the
nine
months ended
June 30, 2016
;
|
|
◦
|
$4 million of restructuring charges related to office buildings during the
nine
months ended
June 30, 2016
;
|
|
•
|
a $2 million remeasurement gain associated with the discontinuation of certain post-employment health and life insurance benefits during the
nine
months ended
June 30, 2017
and $18 million of pension and other postretirement plan remeasurement losses during the
nine
months ended
June 30, 2016
, representing the net impact of a curtailment gain of $92 million related to the current period plan amendments and a $110 million actuarial loss due to changes in discount rates and asset values; and
|
|
•
|
additional charges for legal reserves of $15 million during the
nine
months ended
June 30, 2016
.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
||||||
|
|
June 30
|
||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Net income
|
$
|
85
|
|
|
$
|
247
|
|
|
Income tax benefit
|
(49
|
)
|
|
(39
|
)
|
||
|
Net interest and other financing expense
|
203
|
|
|
125
|
|
||
|
Depreciation and amortization
(a)
|
206
|
|
|
222
|
|
||
|
EBITDA
|
445
|
|
|
555
|
|
||
|
Income from discontinued operations (net of tax)
|
(138
|
)
|
|
(186
|
)
|
||
|
Separation, restructuring and other costs, net
|
71
|
|
|
48
|
|
||
|
Environmental reserve adjustment
|
9
|
|
|
15
|
|
||
|
Legacy benefit for former directors
|
—
|
|
|
(11
|
)
|
||
|
Customer claim adjustment
|
—
|
|
|
(5
|
)
|
||
|
Loss (gain) on pension and other postretirement plan remeasurements
|
(2
|
)
|
|
18
|
|
||
|
Legal reserve
|
5
|
|
|
15
|
|
||
|
Accelerated depreciation
|
12
|
|
|
5
|
|
||
|
Net loss on acquisitions and divestitures
|
6
|
|
|
—
|
|
||
|
Inventory fair value adjustment
|
1
|
|
|
—
|
|
||
|
Adjusted EBITDA
(b)
|
$
|
409
|
|
|
$
|
454
|
|
|
|
|
|
|
||||
|
(a)
|
Excludes
$12 million
and
$5 million
of accelerated depreciation for the
nine
months ended
June 30, 2017
and
2016
, respectively.
|
|
(b)
|
Includes $7 million of expense and
$36 million
of income during the
nine
months ended
June 30, 2017
and
2016
, respectively, related to net periodic pension and other postretirement costs (income) recognized ratably through the fiscal year. These amounts are comprised of service cost, interest cost, expected return on plan assets, and amortization of prior service credit and is disclosed in further detail in Note J of the Notes to Condensed Consolidated Financial Statements.
|
|
|
Three months ended June 30
|
|
Nine months ended June 30
|
||||||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
||||||
|
Sales
|
$
|
870
|
|
|
$
|
790
|
|
|
$
|
80
|
|
|
$
|
2,380
|
|
|
$
|
2,265
|
|
|
$
|
115
|
|
|
|
Three months ended
|
|
|
Nine months ended
|
|
||||
|
(In millions)
|
June 30, 2017
|
|
|
June 30, 2017
|
|
||||
|
Volume
|
|
$
|
26
|
|
|
|
$
|
107
|
|
|
Pricing
|
|
30
|
|
|
|
17
|
|
||
|
Product mix
|
|
(7
|
)
|
|
|
(25
|
)
|
||
|
Currency exchange
|
|
(8
|
)
|
|
|
(22
|
)
|
||
|
Acquisitions and divestitures
|
|
39
|
|
|
|
38
|
|
||
|
Change in sales
|
|
$
|
80
|
|
|
|
$
|
115
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30
|
|
Nine months ended June 30
|
||||||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
||||||
|
Cost of sales
|
$
|
635
|
|
|
$
|
554
|
|
|
$
|
81
|
|
|
$
|
1,727
|
|
|
$
|
1,581
|
|
|
$
|
146
|
|
|
Gross profit as a percent of sales
|
27.0
|
%
|
|
29.9
|
%
|
|
|
|
|
27.4
|
%
|
|
30.2
|
%
|
|
|
|
||||||
|
|
Three months ended
|
|
|
Nine months ended
|
|
||||
|
(In millions)
|
June 30, 2017
|
|
|
June 30, 2017
|
|
||||
|
Changes in:
|
|
|
|
|
|
||||
|
Volume
|
|
$
|
17
|
|
|
|
$
|
76
|
|
|
Production costs
|
|
28
|
|
|
|
50
|
|
||
|
Acquisitions and divestitures
|
|
28
|
|
|
|
28
|
|
||
|
Currency exchange
|
|
(5
|
)
|
|
|
(15
|
)
|
||
|
Product mix
|
|
(8
|
)
|
|
|
(21
|
)
|
||
|
Customer claim
|
|
5
|
|
|
|
5
|
|
||
|
Pension and other postretirement benefit plans expense (income)
|
|
|
|
|
|
||||
|
(including remeasurements)
|
|
7
|
|
|
|
12
|
|
||
|
Severance and other restructuring costs
|
|
|
|
|
|
||||
|
(including accelerated depreciation)
|
|
9
|
|
|
|
11
|
|
||
|
Change in cost of sales
|
|
$
|
81
|
|
|
|
$
|
146
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30
|
|
Nine months ended June 30
|
||||||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
||||||
|
Selling, general and administrative
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
expense
|
$
|
182
|
|
|
$
|
160
|
|
|
$
|
22
|
|
|
$
|
493
|
|
|
$
|
481
|
|
|
$
|
12
|
|
|
As a percent of sales
|
20.9
|
%
|
|
20.3
|
%
|
|
|
|
|
20.7
|
%
|
|
21.2
|
%
|
|
|
|
||||||
|
•
|
$28 million
of costs related to the separation of Valvoline during the current quarter compared to $28 million in the prior year quarter;
|
|
•
|
an increase of $10 million due to higher pension and other postretirement income in the prior year period due to the transfer of a substantial portion of the U.S. pension plans to Valvoline Inc. during September 2016;
|
|
•
|
$11 million and $16 million in net environmental-related expenses during the current and prior year quarter, respectively; and
|
|
•
|
$11 million of income related to the termination of a legacy benefit for former directors during the prior year quarter.
|
|
•
|
$69 million
of costs related to the separation of Valvoline during the current period compared to $46 million in the prior year period;
|
|
•
|
an increase of $29 million due to higher pension and other postretirement income in the prior year period due to the transfer of a substantial portion of the U.S. pension plans to Valvoline Inc. during September 2016;
|
|
•
|
decreased costs of $12 million due to a post-employment remeasurement gain of $1 million during the current period and pension and other postretirement plan remeasurement losses of $11 million during the prior year period, which consisted of a curtailment gain of $53 million and an actuarial loss of $64 million;
|
|
•
|
$19 million and $33 million in net environmental-related expenses during the current and prior year period, respectively;
|
|
•
|
$5 million and $15 million charges for legal reserves during the current and prior year period, respectively;
|
|
•
|
$11 million of income related to the termination of a legacy benefit for former directors during the prior year period; and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
$4 million of restructuring charges related to office buildings during the prior year period.
|
|
|
Three months ended June 30
|
|
Nine months ended June 30
|
||||||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
||||||
|
Research and development expense
|
$
|
20
|
|
|
$
|
22
|
|
|
$
|
(2
|
)
|
|
$
|
61
|
|
|
$
|
66
|
|
|
$
|
(5
|
)
|
|
|
Three months ended June 30
|
|
Nine months ended June 30
|
||||||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
||||||
|
Equity and other income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Equity income
|
$
|
—
|
|
|
$
|
1
|
|
|
$
|
(1
|
)
|
|
$
|
—
|
|
|
$
|
1
|
|
|
$
|
(1
|
)
|
|
Other income
|
4
|
|
|
2
|
|
|
2
|
|
|
9
|
|
|
6
|
|
|
3
|
|
||||||
|
|
$
|
4
|
|
|
$
|
3
|
|
|
$
|
1
|
|
|
$
|
9
|
|
|
$
|
7
|
|
|
$
|
2
|
|
|
|
Three months ended June 30
|
|
Nine months ended June 30
|
||||||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
||||||
|
Net interest and other
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
financing expense (income)
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Interest expense
|
$
|
41
|
|
|
$
|
44
|
|
|
$
|
(3
|
)
|
|
$
|
199
|
|
|
$
|
131
|
|
|
$
|
68
|
|
|
Interest income
|
(1
|
)
|
|
(2
|
)
|
|
1
|
|
|
(3
|
)
|
|
(4
|
)
|
|
1
|
|
||||||
|
Available-for-sale securities income
|
(2
|
)
|
|
(2
|
)
|
|
—
|
|
|
(9
|
)
|
|
(6
|
)
|
|
(3
|
)
|
||||||
|
Other financing costs
|
13
|
|
|
—
|
|
|
13
|
|
|
16
|
|
|
4
|
|
|
12
|
|
||||||
|
|
$
|
51
|
|
|
$
|
40
|
|
|
$
|
11
|
|
|
$
|
203
|
|
|
$
|
125
|
|
|
$
|
78
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30
|
|
Nine months ended June 30
|
||||||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
||||||
|
Net gain (loss) on acquisitions
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
and divestitures
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Pharmachem acquisition
|
$
|
(5
|
)
|
|
$
|
—
|
|
|
$
|
(5
|
)
|
|
$
|
(5
|
)
|
|
$
|
—
|
|
|
$
|
(5
|
)
|
|
Specialty Ingredients joint venture
|
(4
|
)
|
|
—
|
|
|
(4
|
)
|
|
(4
|
)
|
|
—
|
|
|
(4
|
)
|
||||||
|
Kelowna
|
—
|
|
|
2
|
|
|
(2
|
)
|
|
—
|
|
|
2
|
|
|
(2
|
)
|
||||||
|
Composites manufacturing facility
|
4
|
|
|
—
|
|
|
4
|
|
|
4
|
|
|
—
|
|
|
4
|
|
||||||
|
Other
|
(1
|
)
|
|
1
|
|
|
(2
|
)
|
|
(2
|
)
|
|
1
|
|
|
(3
|
)
|
||||||
|
|
$
|
(6
|
)
|
|
$
|
3
|
|
|
$
|
(9
|
)
|
|
$
|
(7
|
)
|
|
$
|
3
|
|
|
$
|
(10
|
)
|
|
|
Three months ended June 30
|
|
Nine months ended June 30
|
||||||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
||||||
|
Income tax benefit
|
$
|
(4
|
)
|
|
$
|
(4
|
)
|
|
$
|
—
|
|
|
$
|
(49
|
)
|
|
$
|
(39
|
)
|
|
$
|
(10
|
)
|
|
Effective tax rate
|
20
|
%
|
|
(20
|
)%
|
|
|
|
|
48
|
%
|
|
(177
|
)%
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30
|
|
Nine months ended June 30
|
||||||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
||||||
|
Income (loss) from discontinued
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
operations (net of tax)
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Valvoline
|
$
|
12
|
|
|
$
|
73
|
|
|
$
|
(61
|
)
|
|
$
|
161
|
|
|
$
|
214
|
|
|
$
|
(53
|
)
|
|
Asbestos-related litigation
|
(25
|
)
|
|
(30
|
)
|
|
5
|
|
|
(25
|
)
|
|
(30
|
)
|
|
5
|
|
||||||
|
Water Technologies
|
(1
|
)
|
|
4
|
|
|
(5
|
)
|
|
2
|
|
|
2
|
|
|
—
|
|
||||||
|
|
$
|
(14
|
)
|
|
$
|
47
|
|
|
$
|
(61
|
)
|
|
$
|
138
|
|
|
$
|
186
|
|
|
$
|
(48
|
)
|
|
|
Three months ended June 30
|
|
Nine months ended June 30
|
||||||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
||||||
|
Net income attributable to
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
noncontrolling interest
|
$
|
3
|
|
|
$
|
—
|
|
|
$
|
3
|
|
|
$
|
27
|
|
|
$
|
—
|
|
|
$
|
27
|
|
|
|
Three months ended June 30
|
|
Nine months ended June 30
|
||||||||||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
2017
|
|
|
2016
|
|
|
Change
|
|
||||||
|
Other comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
(loss) (net of taxes)
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Unrealized translation gain (loss)
|
$
|
105
|
|
|
$
|
(46
|
)
|
|
$
|
151
|
|
|
$
|
19
|
|
|
$
|
(26
|
)
|
|
$
|
45
|
|
|
Pension and postretirement
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
obligation adjustment
|
—
|
|
|
—
|
|
|
—
|
|
|
(4
|
)
|
|
21
|
|
|
(25
|
)
|
||||||
|
Net change in available-for-sale
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
securities
|
4
|
|
|
4
|
|
|
—
|
|
|
10
|
|
|
13
|
|
|
(3
|
)
|
||||||
|
|
$
|
109
|
|
|
$
|
(42
|
)
|
|
$
|
151
|
|
|
$
|
25
|
|
|
$
|
8
|
|
|
$
|
17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
For the three months ended
June 30, 2017
, the unrealized gain from foreign currency translation adjustments was
$105 million
compared to a loss of
$46 million
for the three months ended
June 30, 2016
. The fluctuations in unrealized translation gains and losses is primarily due to translating foreign subsidiary financial statements from local currencies to U.S. Dollars.
|
|
•
|
Gains of
$4 million
on available-for-sale securities, net of tax, related to restricted investments, were recognized within other comprehensive income during each of the three months ended
June 30, 2017
and
2016
.
|
|
•
|
For the
nine
months ended
June 30, 2017
, the unrealized gain from foreign currency translation adjustments was income of
$19 million
compared to a loss of
$26 million
for the
nine
months ended
June 30, 2016
. The fluctuations in unrealized translation gains and losses are primarily due to translating foreign subsidiary financial statements from local currencies to U.S. Dollars.
|
|
•
|
Pension and postretirement obligation adjustment was a loss of
$4 million
for the
nine
months ended
June 30, 2017
compared to income of
$21 million
for the
nine
months ended
June 30, 2016
. Of these amounts,
$4 million
and
$34 million
during the current and prior year periods, respectively, of unrecognized prior service credits, net of tax, relating to pension and other postretirement benefit plans were amortized and reclassified into net income. Additional unrecognized prior service credits, net of tax, of
$55 million
during the prior year period were included in other comprehensive income (loss) as a result of the pension and other postretirement plan remeasurements.
|
|
•
|
Gains of
$10 million
and
$13 million
on available-for-sale securities, net of tax, related to restricted investments, were recognized within other comprehensive income (loss) during the
nine
months ended
June 30, 2017
and
2016
, respectively.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Sales
|
|
|
|
|
|
|
|
||||||||
|
Specialty Ingredients
|
$
|
591
|
|
|
$
|
552
|
|
|
$
|
1,617
|
|
|
$
|
1,557
|
|
|
Composites
|
209
|
|
|
174
|
|
|
561
|
|
|
508
|
|
||||
|
Intermediates and Solvents
|
70
|
|
|
64
|
|
|
202
|
|
|
200
|
|
||||
|
|
$
|
870
|
|
|
$
|
790
|
|
|
$
|
2,380
|
|
|
$
|
2,265
|
|
|
Operating income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Specialty Ingredients
|
$
|
58
|
|
|
$
|
66
|
|
|
$
|
172
|
|
|
$
|
169
|
|
|
Composites
|
22
|
|
|
17
|
|
|
50
|
|
|
55
|
|
||||
|
Intermediates and Solvents
|
2
|
|
|
(1
|
)
|
|
(8
|
)
|
|
5
|
|
||||
|
Unallocated and other
|
(45
|
)
|
|
(25
|
)
|
|
(106
|
)
|
|
(85
|
)
|
||||
|
|
$
|
37
|
|
|
$
|
57
|
|
|
$
|
108
|
|
|
$
|
144
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Specialty Ingredients
|
$
|
70
|
|
|
$
|
61
|
|
|
$
|
178
|
|
|
$
|
184
|
|
|
Composites
|
5
|
|
|
6
|
|
|
16
|
|
|
16
|
|
||||
|
Intermediates and Solvents
|
8
|
|
|
8
|
|
|
23
|
|
|
23
|
|
||||
|
Unallocated and other
|
—
|
|
|
2
|
|
|
1
|
|
|
4
|
|
||||
|
|
$
|
83
|
|
|
$
|
77
|
|
|
$
|
218
|
|
|
$
|
227
|
|
|
Operating information
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Specialty Ingredients
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Sales per shipping day
|
$
|
9.2
|
|
|
$
|
8.6
|
|
|
$
|
8.6
|
|
|
$
|
8.2
|
|
|
Metric tons sold (thousands)
|
83.7
|
|
|
81.8
|
|
|
237.0
|
|
|
227.8
|
|
||||
|
Gross profit as a percent of sales
(a)
|
30.6
|
%
|
|
33.2
|
%
|
|
32.4
|
%
|
|
33.6
|
%
|
||||
|
Composites
|
|
|
|
|
|
|
|
|
|
||||||
|
Sales per shipping day
|
$
|
3.3
|
|
|
$
|
2.7
|
|
|
$
|
3.0
|
|
|
$
|
2.7
|
|
|
Metric tons sold (thousands)
|
88.5
|
|
|
80.2
|
|
|
251.6
|
|
|
233.9
|
|
||||
|
Gross profit as a percent of sales
(a)
|
21.0
|
%
|
|
23.3
|
%
|
|
20.2
|
%
|
|
23.6
|
%
|
||||
|
Intermediates and Solvents
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Sales per shipping day
|
1.1
|
|
|
1.0
|
|
|
1.1
|
|
|
1.1
|
|
||||
|
Metric tons sold (thousands)
|
34.4
|
|
|
34.5
|
|
|
109.8
|
|
|
103.2
|
|
||||
|
Gross profit as a percent of sales (a)
|
14.3
|
%
|
|
9.0
|
%
|
|
6.7
|
%
|
|
13.3
|
%
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
(a)
|
Gross profit is defined as sales, less cost of sales divided by sales.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30, 2017
|
|
Nine months ended June 30, 2017
|
||||||||||||||
|
Sales by Geography
|
Specialty Ingredients
|
|
Composites
|
|
Intermediates and Solvents
|
|
Specialty Ingredients
|
|
Composites
|
|
Intermediates and Solvents
|
||||||
|
North America
|
40
|
%
|
|
48
|
%
|
|
21
|
%
|
|
40
|
%
|
|
48
|
%
|
|
22
|
%
|
|
Europe
|
31
|
%
|
|
29
|
%
|
|
60
|
%
|
|
30
|
%
|
|
29
|
%
|
|
58
|
%
|
|
Asia Pacific
|
19
|
%
|
|
15
|
%
|
|
16
|
%
|
|
20
|
%
|
|
15
|
%
|
|
17
|
%
|
|
Latin America & other
|
10
|
%
|
|
8
|
%
|
|
3
|
%
|
|
10
|
%
|
|
8
|
%
|
|
3
|
%
|
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
Three months ended June 30, 2016
|
|
Nine months ended June 30, 2016
|
||||||||||||||
|
Sales by Geography
|
Specialty Ingredients
|
|
Composites
|
|
Intermediates and Solvents
|
|
Specialty Ingredients
|
|
Composites
|
|
Intermediates and Solvents
|
||||||
|
North America
|
39
|
%
|
|
51
|
%
|
|
21
|
%
|
|
39
|
%
|
|
50
|
%
|
|
22
|
%
|
|
Europe
|
32
|
%
|
|
30
|
%
|
|
61
|
%
|
|
32
|
%
|
|
31
|
%
|
|
59
|
%
|
|
Asia Pacific
|
19
|
%
|
|
14
|
%
|
|
14
|
%
|
|
19
|
%
|
|
13
|
%
|
|
15
|
%
|
|
Latin America & other
|
10
|
%
|
|
5
|
%
|
|
4
|
%
|
|
10
|
%
|
|
6
|
%
|
|
4
|
%
|
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Operating income
|
$
|
58
|
|
|
$
|
66
|
|
|
$
|
172
|
|
|
$
|
169
|
|
|
Depreciation and amortization
(a)
|
59
|
|
|
61
|
|
|
167
|
|
|
180
|
|
||||
|
EBITDA
|
117
|
|
|
127
|
|
|
339
|
|
|
349
|
|
||||
|
Severance and other restructuring costs
|
2
|
|
|
4
|
|
|
2
|
|
|
(1
|
)
|
||||
|
Environmental reserve adjustment
|
—
|
|
|
2
|
|
|
—
|
|
|
2
|
|
||||
|
Accelerated depreciation
|
11
|
|
|
—
|
|
|
11
|
|
|
4
|
|
||||
|
Customer claim adjustment
|
—
|
|
|
(5
|
)
|
|
—
|
|
|
(5
|
)
|
||||
|
Inventory fair value adjustment
|
1
|
|
|
—
|
|
|
1
|
|
|
—
|
|
||||
|
Adjusted EBITDA
|
$
|
131
|
|
|
$
|
128
|
|
|
$
|
353
|
|
|
$
|
349
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
(a)
|
Excludes
$11 million
of accelerated depreciation for the three and nine months ended June 30, 2017 and
$4 million
of accelerated depreciation for the
nine
months ended
June 30, 2016
.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Operating income
|
$
|
22
|
|
|
$
|
17
|
|
|
$
|
50
|
|
|
$
|
55
|
|
|
Depreciation and amortization
|
5
|
|
|
6
|
|
|
16
|
|
|
16
|
|
||||
|
EBITDA
|
$
|
27
|
|
|
$
|
23
|
|
|
$
|
66
|
|
|
$
|
71
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Operating income
|
$
|
2
|
|
|
$
|
(1
|
)
|
|
$
|
(8
|
)
|
|
$
|
5
|
|
|
Depreciation and amortization
|
8
|
|
|
8
|
|
|
23
|
|
|
23
|
|
||||
|
EBITDA
|
$
|
10
|
|
|
$
|
7
|
|
|
$
|
15
|
|
|
$
|
28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
Nine months ended
|
||||||||||||
|
|
June 30
|
|
June 30
|
||||||||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
|
Pension and other postretirement net periodic income
|
|
|
|
|
|
|
|
||||||||
|
(excluding service cost)
|
$
|
—
|
|
|
$
|
17
|
|
|
$
|
1
|
|
|
$
|
50
|
|
|
Gain (loss) on pension and other postretirement
|
|
|
|
|
|
|
|
||||||||
|
plan remeasurements
|
—
|
|
|
—
|
|
|
2
|
|
|
(18
|
)
|
||||
|
Restructuring activities (includes separation,
|
|
|
|
|
|
|
|
||||||||
|
severance and stranded divestiture costs)
|
(31
|
)
|
|
(37
|
)
|
|
(79
|
)
|
|
(80
|
)
|
||||
|
Environmental expense for divested businesses
|
(9
|
)
|
|
(15
|
)
|
|
(17
|
)
|
|
(32
|
)
|
||||
|
Legal reserve
|
—
|
|
|
—
|
|
|
(5
|
)
|
|
(15
|
)
|
||||
|
Other income (expense)
|
(5
|
)
|
|
10
|
|
|
(8
|
)
|
|
10
|
|
||||
|
Total income (expense)
|
$
|
(45
|
)
|
|
$
|
(25
|
)
|
|
$
|
(106
|
)
|
|
$
|
(85
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
||||||
|
|
June 30
|
||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Cash provided (used) by:
|
|
|
|
||||
|
Operating activities from continuing operations
|
$
|
114
|
|
|
$
|
235
|
|
|
Investing activities from continuing operations
|
(779
|
)
|
|
(103
|
)
|
||
|
Financing activities from continuing operations
|
164
|
|
|
(234
|
)
|
||
|
Discontinued operations
|
(187
|
)
|
|
66
|
|
||
|
Effect of currency exchange rate changes on cash and cash equivalents
|
(8
|
)
|
|
(6
|
)
|
||
|
Net decrease in cash and cash equivalents
|
$
|
(696
|
)
|
|
$
|
(42
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
||||||
|
|
June 30
|
||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Cash flows provided (used) by operating activities from continuing operations
|
|
|
|
||||
|
Net income
|
$
|
85
|
|
|
$
|
247
|
|
|
Income from discontinued operations (net of tax)
|
(138
|
)
|
|
(186
|
)
|
||
|
Adjustments to reconcile income from continuing operations to
|
|
|
|
|
|
||
|
cash flows from operating activities
|
|
|
|
|
|
||
|
Depreciation and amortization
|
218
|
|
|
227
|
|
||
|
Original issue discount and debt issuance cost amortization
|
108
|
|
|
9
|
|
||
|
Deferred income taxes
|
(4
|
)
|
|
—
|
|
||
|
Equity income from affiliates
|
—
|
|
|
(1
|
)
|
||
|
Distributions from equity affiliates
|
1
|
|
|
1
|
|
||
|
Stock based compensation expense
|
14
|
|
|
23
|
|
||
|
Loss on early retirement of debt
|
9
|
|
|
—
|
|
||
|
Gain on available-for-sale securities
|
(9
|
)
|
|
(6
|
)
|
||
|
Net loss (gain) on divestitures
|
4
|
|
|
(3
|
)
|
||
|
Pension contributions
|
(6
|
)
|
|
(24
|
)
|
||
|
Loss (gain) on pension and other postretirement plan remeasurements
|
(2
|
)
|
|
18
|
|
||
|
Change in operating assets and liabilities
(a)
|
(166
|
)
|
|
(70
|
)
|
||
|
Total cash flows provided by operating activities from continuing operations
|
$
|
114
|
|
|
$
|
235
|
|
|
|
|
|
|
||||
|
•
|
Accounts receivable - The current period had a cash outflow of $76 million compared to a cash inflow of $36 million during the prior year period. The cash outflow during the current period is primarily due to higher sales compared to the prior year period.
|
|
•
|
Inventory - The current period had a cash outflow of $16 million compared to a cash inflow of $46 million during the prior year period, which were primarily due to sales volumes and inventory management strategies.
|
|
•
|
Trade and other payables - The current period had a cash inflow of $4 million compared to a cash outflow of $137 million during the prior year period, which were primarily driven by seasonal fluctuations in trade payables and incentive compensation payouts from the prior year paid during the first quarter of each fiscal year.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
||||||
|
|
June 30
|
||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Cash flows provided (used) by investing activities from continuing operations
|
|
|
|
||||
|
Additions to property, plant and equipment
|
$
|
(126
|
)
|
|
$
|
(150
|
)
|
|
Proceeds from disposal of property, plant and equipment
|
4
|
|
|
3
|
|
||
|
Purchase of operations - net of cash acquired
|
(680
|
)
|
|
—
|
|
||
|
Proceeds from sale of operations or equity investments
|
4
|
|
|
18
|
|
||
|
Net purchase of funds restricted for specific transactions
|
(2
|
)
|
|
(4
|
)
|
||
|
Reimbursements from restricted investments
|
19
|
|
|
24
|
|
||
|
Purchases of available-for-sale securities
|
(19
|
)
|
|
(4
|
)
|
||
|
Proceeds from sales of available-for-sale securities
|
19
|
|
|
4
|
|
||
|
Proceeds from the settlement of derivative instruments
|
5
|
|
|
8
|
|
||
|
Payments for the settlement of derivative instruments
|
(3
|
)
|
|
(2
|
)
|
||
|
Total cash flows used by investing activities from continuing operations
|
$
|
(779
|
)
|
|
$
|
(103
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
||||||
|
|
June 30
|
||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Cash flows provided (used) by financing activities from continuing operations
|
|
|
|
||||
|
Proceeds from issuance of long-term debt
|
$
|
1,100
|
|
|
$
|
—
|
|
|
Repayment of long-term debt
|
(913
|
)
|
|
(50
|
)
|
||
|
Premium on long-term debt repayment
|
(17
|
)
|
|
—
|
|
||
|
Proceeds from short-term debt
|
69
|
|
|
389
|
|
||
|
Repurchase of common stock
|
—
|
|
|
(500
|
)
|
||
|
Debt issuance costs
|
(15
|
)
|
|
(2
|
)
|
||
|
Cash dividends paid
|
(62
|
)
|
|
(72
|
)
|
||
|
Excess tax benefits related to share-based payments
|
2
|
|
|
1
|
|
||
|
Total cash flows provided (used) by financing activities from continuing operations
|
$
|
164
|
|
|
$
|
(234
|
)
|
|
|
Nine months ended
|
||||||
|
|
June 30
|
||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Cash used by discontinued operations
|
|
|
|
||||
|
Operating cash flows
|
$
|
123
|
|
|
$
|
170
|
|
|
Investing cash flows
|
(293
|
)
|
|
(104
|
)
|
||
|
Financing cash flows
|
(17
|
)
|
|
—
|
|
||
|
Total cash provided (used) by discontinued operations
|
$
|
(187
|
)
|
|
$
|
66
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended
|
||||||
|
|
June 30
|
||||||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Cash flows provided by operating activities from continuing operations
|
$
|
114
|
|
|
$
|
235
|
|
|
Adjustments:
|
|
|
|
|
|
||
|
Additions to property, plant and equipment
|
(126
|
)
|
|
(150
|
)
|
||
|
Free cash flows
|
$
|
(12
|
)
|
|
$
|
85
|
|
|
|
June 30
|
|
|
September 30
|
|
||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Cash and cash equivalents
|
$
|
492
|
|
|
$
|
1,017
|
|
|
|
|
|
|
||||
|
Unused borrowing capacity
|
|
|
|
|
|
||
|
2017 Revolving Credit Facility
|
$
|
620
|
|
|
$
|
—
|
|
|
2015 Revolving Credit Facility
|
—
|
|
|
742
|
|
||
|
Accounts receivable securitization facility
|
5
|
|
|
80
|
|
||
|
|
June 30
|
|
|
September 30
|
|
||
|
(In millions)
|
2017
|
|
|
2016
|
|
||
|
Short-term debt
|
$
|
223
|
|
|
$
|
170
|
|
|
Long-term debt (including current portion and debt issuance cost discounts)
(a)
|
2,590
|
|
|
2,325
|
|
||
|
Total debt
|
$
|
2,813
|
|
|
$
|
2,495
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuer Purchases of Equity Securities
|
|||||||||||||||
|
Q3 Fiscal Periods
|
Total Number of Shares Purchased
|
Average Price Paid Per Share, including commission
|
|
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
|
|
Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (in millions)(1)
|
|||||||||
|
April 1, 2017 to April 30, 2017:
|
|
|
|
|
|
|
|
$
|
500
|
|
|
||||
|
Employee Tax Withholdings
|
5,175
|
|
(2)(3)
|
|
$
|
123.88
|
|
|
—
|
|
|
|
|
||
|
May 1, 2017 to May 31, 2017:
|
|
|
|
|
|
|
|
|
500
|
|
|
||||
|
Employee Tax Withholdings
|
—
|
|
|
|
—
|
|
|
—
|
|
|
|
|
|||
|
June 1, 2017 to June 30, 2017:
|
|
|
|
|
|
|
|
500
|
|
|
|||||
|
Employee Tax Withholdings
|
2,404
|
|
(2)(3)
|
|
62.93
|
|
|
—
|
|
|
|
|
|||
|
Total
|
7,579
|
|
|
|
|
|
—
|
|
|
$
|
500
|
|
|
||
|
(a) Exhibits
|
|
|
10.1
|
Stock Purchase Agreement, dated April 14, 2017, by and among Ashland LLC, Pharmachem Laboratories, Inc., the holders of common stock of Pharmachem Laboratories, Inc., Dr. David Peele, and Photon SH Representative LLC, solely as the shareholders’ representative (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on May 18, 2017 (SEC File No. 333-211719) and incorporated herein by reference).
|
|
|
|
|
10.2
|
Amendment No. 1 to the Stock Purchase Agreement, dated May 16, 2017, by and among Ashland LLC, Pharmachem Laboratories, Inc., the holders of common stock of Pharmachem Laboratories, Inc., Dr. David Peele, and Photon SH Representative LLC, solely as the shareholders’ representative (filed as Exhibit 2.2 to Ashland’s Form 8-K filed on May 18, 2017 (SEC File No. 333-211719) and incorporated herein by reference).
|
|
|
|
|
10.3
|
Credit Agreement, dated as of May 17, 2017, among Ashland LLC, as Borrower, The Bank of Nova Scotia, as Administrative Agent, Swing Line Lender and an L/C Issuer, each Lender and L/C Issuer party thereto and the other agents party thereto (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on May 18, 2017 (SEC File No. 333-211719) and incorporated herein by reference).
|
|
|
|
|
10.4
|
Amendment No. 1 dated as of May 19, 2017, among Ashland LLC, as Borrower (the “Borrower”), certain subsidiaries of the Borrower, The Bank of Nova Scotia, as Administrative Agent (the “Administrative Agent”), and Citibank, N.A., as the Incremental Revolving Credit Lender, to the Credit Agreement dated as of May 17, 2017, among the Borrower, the Administrative Agent, each lender and letter of credit issuer party thereto and the other agents party thereto (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on May 22, 2017 (SEC File No. 333-211719) and incorporated herein by reference).
|
|
|
|
|
10.5
|
Amendment No. 2 dated as of June 14, 2017, among Ashland LLC, as Borrower (the “Borrower”), certain subsidiaries of the Borrower, The Bank of Nova Scotia, as Administrative Agent (the “Administrative Agent”), and Citibank, N.A., as the Term B Lender, to the Credit Agreement dated as of May 17, 2017, among the Borrower, the Administrative Agent, each lender and letter of credit issuer party thereto and the other agents party thereto (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on June 14, 2017 (SEC File No. 333-211719) and incorporated herein by reference).
|
|
|
|
|
10.6*
|
Fifteenth Amendment dated as of May 17, 2017 to the Transfer and Administration Agreement dated as of August 31, 2012 among Ashland LLC, as Master Servicer, CVG Capital III LLC, as SPV, the Originators, the Investors, Letter of Credit Issuers, Managing Agents and Administrators party thereto, and The Bank of Nova Scotia, as agent for the Investors.
|
|
|
|
|
12*
|
Computation of Ratio of Earnings to Fixed Charges.
|
|
|
|
|
31.1*
|
Certificate of William A. Wulfsohn, Chief Executive Officer of Ashland pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
31.2*
|
Certificate of J. Kevin Willis, Chief Financial Officer of Ashland pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
32*
|
Certificate of William A. Wulfsohn, Chief Executive Officer of Ashland, and J. Kevin Willis, Chief Financial Officer of Ashland pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
101.INS**
|
XBRL Instance Document.
|
|
|
|
|
101.SCH**
|
XBRL Taxonomy Extension Schema Document.
|
|
|
|
|
101.CAL**
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
|
|
|
101.DEF**
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
|
|
|
101.LAB**
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
|
|
|
101.PRE**
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
|
Ashland Global Holdings Inc.
|
|
|
(Registrant)
|
|
August 4, 2017
|
/s/ J. Kevin Willis
|
|
|
J. Kevin Willis
|
|
|
Senior Vice President and Chief Financial Officer
(on behalf of the Registrant and as principal
financial officer)
|
|
(a) Exhibits
|
|
|
10.1
|
Stock Purchase Agreement, dated April 14, 2017, by and among Ashland LLC, Pharmachem Laboratories, Inc., the holders of common stock of Pharmachem Laboratories, Inc., Dr. David Peele, and Photon SH Representative LLC, solely as the shareholders’ representative (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on May 18, 2017 (SEC File No. 333-211719) and incorporated herein by reference).
|
|
|
|
|
10.2
|
Amendment No. 1 to the Stock Purchase Agreement, dated May 16, 2017, by and among Ashland LLC, Pharmachem Laboratories, Inc., the holders of common stock of Pharmachem Laboratories, Inc., Dr. David Peele, and Photon SH Representative LLC, solely as the shareholders’ representative (filed as Exhibit 2.2 to Ashland’s Form 8-K filed on May 18, 2017 (SEC File No. 333-211719) and incorporated herein by reference).
|
|
|
|
|
10.3
|
Credit Agreement, dated as of May 17, 2017, among Ashland LLC, as Borrower, The Bank of Nova Scotia, as Administrative Agent, Swing Line Lender and an L/C Issuer, each Lender and L/C Issuer party thereto and the other agents party thereto (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on May 18, 2017 (SEC File No. 333-211719) and incorporated herein by reference).
|
|
|
|
|
10.4
|
Amendment No. 1 dated as of May 19, 2017, among Ashland LLC, as Borrower (the “Borrower”), certain subsidiaries of the Borrower, The Bank of Nova Scotia, as Administrative Agent (the “Administrative Agent”), and Citibank, N.A., as the Incremental Revolving Credit Lender, to the Credit Agreement dated as of May 17, 2017, among the Borrower, the Administrative Agent, each lender and letter of credit issuer party thereto and the other agents party thereto (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on May 22, 2017 (SEC File No. 333-211719) and incorporated herein by reference).
|
|
|
|
|
10.5
|
Amendment No. 2 dated as of June 14, 2017, among Ashland LLC, as Borrower (the “Borrower”), certain subsidiaries of the Borrower, The Bank of Nova Scotia, as Administrative Agent (the “Administrative Agent”), and Citibank, N.A., as the Term B Lender, to the Credit Agreement dated as of May 17, 2017, among the Borrower, the Administrative Agent, each lender and letter of credit issuer party thereto and the other agents party thereto (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on June 14, 2017 (SEC File No. 333-211719) and incorporated herein by reference).
|
|
|
|
|
10.6*
|
Fifteenth Amendment dated as of May 17, 2017 to the Transfer and Administration Agreement dated as of August 31, 2012 among Ashland LLC, as Master Servicer, CVG Capital III LLC, as SPV, the Originators, the Investors, Letter of Credit Issuers, Managing Agents and Administrators party thereto, and The Bank of Nova Scotia, as agent for the Investors.
|
|
|
|
|
12*
|
Computation of Ratio of Earnings to Fixed Charges.
|
|
|
|
|
31.1*
|
Certificate of William A. Wulfsohn, Chief Executive Officer of Ashland pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
31.2*
|
Certificate of J. Kevin Willis, Chief Financial Officer of Ashland pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
32*
|
Certificate of William A. Wulfsohn, Chief Executive Officer of Ashland, and J. Kevin Willis, Chief Financial Officer of Ashland pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
101.INS**
|
XBRL Instance Document.
|
|
|
|
|
101.SCH**
|
XBRL Taxonomy Extension Schema Document.
|
|
|
|
|
101.CAL**
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
|
|
|
101.DEF**
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
|
|
|
101.LAB**
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
|
|
|
101.PRE**
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|